Recalibrating our near-term estimates while maintaining the firm's inherent strength
11/08/25 -"We have revisited the amortisation expenses and negative FX hedging results for FY2024-25 and, as a result for the current fiscal year, our EPS estimates have been revised downwards. However, our ..."
Pages
62
Language
English
Published on
11/08/25
You may also be interested by these reports :
11/08/25
We have revisited the amortisation expenses and negative FX hedging results for FY2024-25 and, as a result for the current fiscal year, our EPS ...
07/08/25
CZM’s Q3 sales met expectations, driven by Microsurgery, while Ophthalmology remained stable. The FY2024-25 guidance remains unchanged. However, a ...
06/08/25
Fresenius posted encouraging Q2 2025 results, with €5.6bn in sales (+5%) and adjusted EBIT coming ahead of street expectations. Both segments clocked ...
06/08/25
Qiagen exceeded market expectations and management’s guidance in Q2, driven by robust growth in Diagnostic Solutions and contributions from ...